Physician profile
Fara Anzures
NPI 1659498640
$1,246.71
in general payments reported to CMS, 2019-2025
10 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $119 · 2024: $494 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $146.71 | 2025 | Aptima |
| Springworks Therapeutics, INC. | $144.52 | 2025 | Gomekli |
| Sanofi-Aventis U.S. LLC | $139.42 | 2025 | |
| Alnylam Pharmaceuticals INC. | $127.89 | 2024 | Onpattro |
| Abbvie INC. | $124.41 | 2024 | |
| Amgen INC. | $121.58 | 2024 | Repatha |
| Silk Road Medical, INC. | $120.26 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Glaxosmithkline, LLC. | $118.71 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $113.59 | 2025 | Dupixent |
| Amarin Pharma, INC. | $89.62 | 2025 | Vascepa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fara Anzures listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.